Archives: Agenda
Regulatory landscape for AI & Software in UK & Ireland
| A concise overview of how AI and software-based medical technologies are regulated across England and Ireland, highlighting alignment, divergence, and what developers and trial teams need to plan for now. |
Chairperson’s Opening Remarks & LinkedIn Prize Draw
To be in with a chance of winning our LinkedIn Prize Draw, post your most engaging and/or funniest photo from Day 1 of the conference on LinkedIn by 8:00pm on 9 June.
Please include the hashtags:
#OCTUK #OCTIreland #ClinicalTrials #ClinicalOutsourcing #Healthcare #Pharma
And tag both:
- Outsourcing in Clinical Trials Event Series
- Arena International Events Group
We will shortlist three finalists, and the audience will vote for the winner during the Chairpersons’ Opening Remarks on Day 2.
Please note: you must be present in the room at 8:45am to claim the prize. If the winner is not present, the prize will be awarded to the next finalist in attendance.
Adaptive Oncology Trials: Improving Access and the Patient Perspective
| This session explores how adaptive trial designs are changing oncology research, enabling greater flexibility in trial arms and broader use of therapies across indications. We will discuss what this means for patient access and why embedding patient perspectives early is critical to successful study design and delivery. |
Lunch and networking
Afternoon refreshments, networking & Apple prize draw
Lunch and networking
Close of conference
ROUNDTABLE DISCUSSIONS
During the roundtable discussion session, the conference hall will be divided into zones. Delegates can choose which zone they would like to join. Each zone will be led by a table lead/host and will focus on a different challenge within the industry. After 30 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.
| ROUNDTABLE 1: Taking the Wheel: Gaining Control of Your eTMF During Active Trials
Jane Silverwood, Clinical Documental Management Specialist, Owkin |
| ROUNDTABLE 2: Beyond the CRO: What Clinical-Stage Biotech Actually Needs from an Execution Partner
Kamil Sitarz, PhD, EMBA, Chief Operating Officer, Ryvu Therapeutics |
| ROUNDTABLE 3: Developing medicines from analysis of real-world data
Myles Dakin, Chairman & Founder, Hypo-Stream |
| ROUNDTABLE 4: AI in Clinical Trials: Who Owns the Risk When Development is Outsourced?
Surbhi Gupta, Advisor to National AI team, NHS England |
| ROUNDTABLE 5: Can FAST-EU realistically accelerate multinational trial start-up, or will operational reality slow it down?
Victoria Toms, Executive Director, International Accrediting Organisation for Clinical Research (IAOCR) |
From the Health Dividend of Peace to the Economic Dividend of Health: A Tale of Politics, Pragmatism and Progress Strength in Collaboration: How a Unified cancer approach Is driving growth and cross-border innovation
- The Good Friday Agreement: How politics helped deliver the health dividend of peace on the island of Ireland
- The All-Island Cancer Research Institute (AICRI) a united approach to cancer research and innovation
- How a collaborative cancer research and innovation agenda is empowering the island of Ireland to punch above its weight
- How a unified national collaborative clinical trials ecosystem, underpinned by the formation of the National Clinical Trials Oversight Group, is raising the bar and delivering innovative treatments for Irish patients
- Empowering the Economic Dividend of Health: Providing the innovation and research excellence milieu for industry and academic clinical trials and Real-World Evidence studies to flourish North, South, East and West: maximising the opportunities for cross-border success